Anatumomab mafenatox

Source: Wikipedia, the free encyclopedia.
Anatumomab mafenatox
TAG-72
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
  (verify)

Anatumomab mafenatox is a

non-small cell lung cancer,[1] which acts as a tumor-targeted superantigen.[2]

It is a

Fab fragment with an enterotoxin ('mafenatox') of Staphylococcus aureus.[3]

Development was abandoned in 2005.[4]

References

  1. ^ "Active Biotech". activebiotech.com. Retrieved 25 May 2016.
  2. ISBN 9781118354599
    .
  3. ^ "Drug info" (PDF). World Health Organization. Retrieved 25 May 2016.
  4. ^ "Anatumomab mafenatox". AdisInsight. Springer Nature Switzerland AG.


Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Anatumomab_mafenatox&oldid=1160195815"